Raymond James & Associates’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Raymond James & Associates’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-90	Closed	-$25K	–	3774
2019 Q1	$25K	Sell	90 -7	-7%	-$1.52K	﹤0.01%	3521
2018 Q4	$12K	Hold	97	–	–	﹤0.01%	3467
2018 Q3	$40K	Sell	97 -44	-31%	-$20.4K	﹤0.01%	3503
2018 Q2	$76K	Sell	141 -334	-70%	-$178K	﹤0.01%	3421
2018 Q1	$219K	Sell	475 -6	-1%	-$3.27K	﹤0.01%	3083
2017 Q4	$322K	Buy	481 +47	+11%	+$28.4K	﹤0.01%	2789
2017 Q3	$273K	Buy	434 +88	+25%	+$45.8K	﹤0.01%	2852
2017 Q2	$166K	Buy	+346	New	+$211K	﹤0.01%	3032

Other funds holding TCON

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Raymond James & Associates's TCON Position: Q2 2019 in Review

Raymond James & Associates sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2019, closing a stake of 90 shares — an estimated $25K sold.

Raymond James & Associates first reported a position in TCON in Q2 2017 and held it in 8 quarters. The position peaked at $322K in Q4 2017. 25 funds tracked by Wall St. Rank hold TCON as of Q2 2019.

Raymond James & Associates reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
Raymond James & Associates sold 90 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $25K.
Raymond James & Associates first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2017 and held it in 8 quarters.
Raymond James & Associates's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $322K in Q4 2017.
25 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Raymond James & Associates's 13F filing for Q2 2019, filed 6 Aug 2019.